The NMI is a member of the Innovation Alliance Baden-Württemberg. It is involved in application-oriented research at the interface between the life sciences and material science. An interdisciplinary team of scientists is developing new technologies for companies and public research sponsors in the areas of Pharma and Biotech, Biomedicine and Materials Science, and Material Analysis and Electron Microscopy.
The Multiplex Immunoassays Group at the NMI has strong expertise in multiplex miniaturized immunoassays. We are experts in assay development and validation, with unique capabilities for large-scale screening projects with tens of thousands of samples for biomarker discovery and qualification. One strong focus of our group, is serological testing for antibodies following pathogen infection (SARS-CoV-2, hepatitis viruses, MTB etc).
This position is available to start immediately.
In a joint collaboration between the groups “Recombinant Antibody Technologies” of Prof. Ulrich Rothbauer and “Multiplex Immunoassays” of Dr. Nicole Schneiderhan-Marra at the NMI Natural and Medical Sciences Institute in Reutlingen with the group “Molecular Virology” of Prof. Michael Schindler at the University Hospital in Tuebingen we aim to develop novel antibody-derived binding molecules to address individual subtypes of the Dengue virus. Additionally, we aim to develop advanced serological assays to monitor the infectious state and individual immune responses towards an infection with the Dengue virus.
Your contact person
Frau Katja Rösslein